BRIEF-Oncolytics Biotech reports updated data from Phase 2 study of REOLYSIN

Thu Apr 14, 2016 6:49am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

April 14 (Reuters) - Oncolytics Biotech Inc

* Analysis showed a statistically significantly higher percentage of patients surviving two years in test arm versus control arm

* Says at time of data cut off, there were five survivors on study in test arm, and one survivor on study in crossover arm

* Two- and three-year survival for arms may continue to evolve Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)